Alterity Therapeutics meeting with US FDA provides development pathway for ATH434 June 30, 2020August 16, 2022
PBT434 drug candidate shows potential as “next-generation” disease-modifying treatment in Parkinson’s Disease July 17, 2013August 16, 2022